Skip to main content
TechnologyTreatment

Accelerating the development of new cancer drugs in Ontario

Article1 min read

Drs. Lisa Porter and John Trant from the University of Windsor are working to develop a drug to block a protein that is elevated in some types of aggressive cancer. Disrupting the activity of this unique protein complex could slow or stop the disease. By providing researchers such as Porter and Trant with funding support and access to expertise, OICR’s Cancer Therapeutics Innovation Pipeline initiative is enabling the development of the next wave of made-in-Ontario cancer therapies.

Newsletter signup

Cancer solved together — in your inbox

The latest findings, funding, and partnerships from Ontario’s cancer research institute. Briefings and deeper dives.

Subscribe